Aug 2026· Brain Research· pp.
150514
· 0 citations· 110 references
Medicine
TL;DR
Although available evidence supports an association between ferroptosis-related processes and AD pathobiology, no single marker is sufficient to establish ferroptosis in human AD tissue, which restricts the diagnostic and therapeutic interpretation of ferroptosis in AD.
Abstract
Alzheimer's disease (AD) develops through interacting proteinopathic, metabolic, oxidative, and neuroimmune processes. Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation and failure of antioxidant defense systems. This review examines the bidirectional interface between ferroptosis and neuroinflammation in AD and distinguishes direct AD-related evidence from findings derived from experimental models and broader ferroptosis or inflammatory studies. Iron dyshomeostasis, impaired ferroportin-dependent iron export, lipid peroxidation, and reduced glutathione/GPX4-dependent protection may increase neuronal susceptibility to ferroptotic injury. In turn, oxidized lipids and danger-associated molecular patterns released from damaged neurons may activate microglia and astrocytes, engage inflammasome and complement signaling, and amplify inflammatory responses. Conversely, cytokine signaling, altered iron handling, and immune-cell redox and lipid remodeling may further increase ferroptotic vulnerability. We also compare ferroptosis-related markers and pathways in neurons, microglia, and astrocytes and discuss potential therapeutic approaches targeting iron metabolism, lipid peroxidation, GPX4 activity, system xc - function, NRF2-related antioxidant defense, neuroimmune signaling, and multitarget compounds. Although available evidence supports an association between ferroptosis-related processes and AD pathobiology, no single marker is sufficient to establish ferroptosis in human AD tissue. This limitation currently restricts the diagnostic and therapeutic interpretation of ferroptosis in AD.
Understanding the mechanism of these players gives a mechanistic framework for the development of targeted therapeutic and nutritional interventions to reduce neuronal damage and help slow the progression of CNS disorders.
Khuzin Dinislam, V. A. Kataev, Mohammad Rehan Ajmal et al.· Frontiers in Aging Neuroscie...· 0 citations
Current evidence on the molecular mechanisms linking miRNAs and ferroptosis in SCI is summarized, highlighting how miRNA-mediated regulation of ferroptosis contributes to neuronal death, glial responses, and impaired regeneration, and discusses emerging therapeutic strategies targeting this axis to promote neuroprotect...
Raju Poongodi, Tao-Hsiang Yang, Kuender D. Yang et al.· International Journal of Mol...· 0 citations
Overall, pyroptosis provides a novel framework for understanding the interplay between neuroinflammation and neurodegeneration in AD; however, its cell-type-specific roles, stage-dependent effects, and translational potential remain to be fully elucidated.
Xin-Kai Wu, Qiuyan Ye, Ming-Sheng Zi et al.· Molecular and cellular neuro...· 0 citations
A contextual framework is built that specifies when HO-1 activation is protective versus detrimental, organised around three converging determinants: cell-type specificity, iron-handling capacity, and disease stage, which is extended to the often-overlooked dimensions of sex, age, and model heterogeneity, and used to i...
Tanvi Premchandani, M. Qutub, Tejaswini Thave et al.· Brain Research· 1 citation
INTRODUCTION
Neurodegenerative Diseases (NDDs), including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Multiple Sclerosis (MS), are increasingly associated with ferroptosis, a regulated irondependent form of cell death characterised by the exces...
Nainsi Kumari, Shruti Dwivedi, Satyam Yadav et al.· Current Neurovascular Resear...· 0 citations
The review elucidates the molecular mechanisms linking ferroptosis and NMDA receptor overactivation and their impact on P‐gp‐mediated Aβ transport in the AD, providing integrated mechanisms and harnessing their potential for AD therapeutics.
Jotiram Salunkhe, Dr. Vinod Ugale· Drug development research (P...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.